Appl. No. 09/845,715 Reply to Final Office Action of December 14, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (previously presented) An isolated biopolymer marker consisting of amino acid residues 2-12 of SEO ID NO:1.

Claims 2-43. (cancelled)

Claim 44. (new) A method for determining presence of an isolated biopolymer marker indicative of myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) consisting of amino acid residues 2-12 of SEQ ID NO:1 from a mass spectrometric analysis of a sample obtained from a patient comprising:

- (a) preparing said sample for a mass spectrometric analysis by subjecting peptides contained in said sample to chromatography;
- (b) conducting mass spectrometric analysis on said sample as prepared in step (a) to obtain mass spectral profiles of peptides contained therein;

Appl. No. 09/845,715 Reply to Final Office Action of December 14, 2006

- (c) comparing a reference mass spectral profile characteristic of said isolated biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 having an ion peak at about 1348 daltons to mass spectral profiles of peptides obtained from said sample; and
- (d) matching said reference mass spectral profile to a mass spectral profile of a peptide obtained from said sample by identifying said ion peak at about 1348 daltons;

wherein a match confirms presence of a biopolymer marker indicative of myocardial infarction, intracerebral hemorrhage or congestive heart failure consisting of amino acid residues 2-12 of SEQ ID NO:1.

Claim 45. (new) The method of claim 44 wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 46. (new) The method of claim 44 wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), tandem mass spectrometry or a combination thereof.

Appl. No. 09/845,715 Reply to Final Office Action of December 14, 2006

Claim 47. (new) The method of claim 44 wherein said patient is a human.

Claim 48. (new) A kit for determining presence of an isolated biopolymer marker indicative of myocardial infarction, intracerebral hemorrhage or congestive heart failure consisting of amino acid residues 2-12 of SEQ ID NO:1 comprising: (a) a peptide consisting of amino acid residues 2-12 of SEQ ID NO:1 and (b) an antibody that binds to said peptide in a sample obtained from a patient.

Claim 49. (new) The kit of claim 48 wherein said antibody is immobilized on a solid support.

Claim 50. (new) The kit of claim 48 wherein said antibody is labeled.